Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054

2019189 citationsJournal Articlehybrid Open Access

Authors

Mirosław Bryś · Biogen (United States)

Laura Fanning · Biogen (United States)

Serena Hung · Biogen (United States)

Aaron Ellenbogen · Quest Research Institute

Natalia A. Penner · Biogen (United States)

Minhua Yang · Biogen (United States)

Mackenzie Welch ·

Abstract

BIIB054 has favorable safety, tolerability, and pharmacokinetic profiles in volunteers and Parkinson's disease participants, supporting further clinical development. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Neurological disorders and treatments Nuclear Receptors and Signaling

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Movement Disorders

Volume 34, Issue 8, pp. 1154-1163

DOI: 10.1002/mds.27738

Field-Weighted Citation Impact: 16.31